Literature DB >> 30568291

Risk of hypertension among different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies.

Atieh Mirzababaei1,2, Hadis Mozaffari1, Sakineh Shab-Bidar1, Alireza Milajerdi1, Kurosh Djafarian3.   

Abstract

We performed a meta-analysis to assess the association of body mass index (BMI) and metabolic status with the risk of incident hypertension. Relevant studies were identified by searching comprehensive search via PubMed and Scopus search engines up to May 2018 and were analyzed using a random-effects model. Eight prospective studies were included in the analyses with metabolically healthy normal weight (MHNW) as the reference group. Pooled relative risks (RRs) and their 95% confidence intervals (CI) were calculated using random-effects or fixed-effect models when appropriate. Subgroup analysis was applied to define possible sources of heterogeneity. Overall, among 79090 participants, the risk of hypertension in metabolically unhealthy obese (MUHO) and metabolically healthy obese phenotypes (MHO) increased compared with the reference group (pooled effect size = 1.95, 95%CI: 1.87-2.04, P < 0.001 vs pooled effect size: 1.54, 95%CI: 1.48-1.61, P < 0.001, respectively). Also, a significant positive association between metabolically unhealthy normal weight (MUHNW) phenotype and the risk of hypertension was observed (pooled effect size = 1.48, 95%CI: 1.41-1.55, P < 0.001). Metabolically unhealthy overweight (MUHOW) and metabolically healthy overweight (MHOW) phenotypes had greater risk of hypertension compared with the MHNW phenotype (pooled effect size = 1.50, 95%CI: 1.13-1.71, P < 0.001 and pooled effect size = 1.18, 95%CI: 1.11-1.27, P < 0.001). This meta-analysis revealed that individuals with metabolic abnormality had a higher risk for hypertension and also suggests that MHOW/ MHO are not a benign condition. We are refuting the notion that overweight and obesity without metabolic abnormalities are benign conditions in all population.

Entities:  

Mesh:

Year:  2018        PMID: 30568291     DOI: 10.1038/s41371-018-0146-y

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  53 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis.

Authors:  Ruizhi Zheng; Dan Zhou; Yimin Zhu
Journal:  J Epidemiol Community Health       Date:  2016-04-28       Impact factor: 3.710

3.  "Metabolically Healthy" Obesity and Hyperuricemia Increase Risk for Hypertension and Diabetes: 5-year Japanese Cohort Study.

Authors:  Masanari Kuwabara; Remi Kuwabara; Ichiro Hisatome; Koichiro Niwa; Carlos A Roncal-Jimenez; Petter Bjornstad; Ana Andres-Hernando; Yuka Sato; Thomas Jensen; Gabriela Garcia; Minoru Ohno; James O Hill; Miguel A Lanaspa; Richard J Johnson
Journal:  Obesity (Silver Spring)       Date:  2017-09-18       Impact factor: 5.002

4.  Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals.

Authors:  KoKo Aung; Carlos Lorenzo; Marco A Hinojosa; Steven M Haffner
Journal:  J Clin Endocrinol Metab       Date:  2013-11-20       Impact factor: 5.958

5.  Evaluating the risk of hypertension according to the metabolic health status stratified by degree of obesity.

Authors:  Jae-Hong Ryoo; Sung Keun Park; Chang-Mo Oh; Young-Jun Choi; Ju Youn Chung; Woo Taek Ham; Taegi Jung
Journal:  J Am Soc Hypertens       Date:  2016-11-02

6.  Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study.

Authors:  Karla M Pou; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; Pal Maurovich-Horvat; Martin G Larson; John F Keaney; James B Meigs; Izabella Lipinska; Sekar Kathiresan; Joanne M Murabito; Christopher J O'Donnell; Emelia J Benjamin; Caroline S Fox
Journal:  Circulation       Date:  2007-08-20       Impact factor: 29.690

7.  Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

Authors:  J M Chan; E B Rimm; G A Colditz; M J Stampfer; W C Willett
Journal:  Diabetes Care       Date:  1994-09       Impact factor: 19.112

8.  Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality.

Authors:  Mark Hamer; Emmanuel Stamatakis
Journal:  J Clin Endocrinol Metab       Date:  2012-04-16       Impact factor: 5.958

9.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.

Authors:  Gary Whitlock; Sarah Lewington; Paul Sherliker; Robert Clarke; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Rory Collins; Richard Peto
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

10.  Defining metabolically healthy obesity: role of dietary and lifestyle factors.

Authors:  Catherine M Phillips; Christina Dillon; Janas M Harrington; Vera J C McCarthy; Patricia M Kearney; Anthony P Fitzgerald; Ivan J Perry
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more
  8 in total

Review 1.  Lifestyle interventions for the prevention and treatment of hypertension.

Authors:  Pedro L Valenzuela; Pedro Carrera-Bastos; Beatriz G Gálvez; Gema Ruiz-Hurtado; José M Ordovas; Luis M Ruilope; Alejandro Lucia
Journal:  Nat Rev Cardiol       Date:  2020-10-09       Impact factor: 32.419

2.  Children's Lipid Accumulation Product Combining Visceral Adiposity Index is a Novel Indicator for Predicting Unhealthy Metabolic Phenotype Among Chinese Children and Adolescents.

Authors:  Yangyang Dong; Ling Bai; Rongrong Cai; Jinyu Zhou; Wenqing Ding
Journal:  Diabetes Metab Syndr Obes       Date:  2021-11-23       Impact factor: 3.168

3.  Risk of Stroke Among Different Metabolic Obesity Phenotypes: A Systematic Review and Meta-Analysis.

Authors:  Miaomiao Meng; Yixin Guo; Zhuoran Kuang; Lingling Liu; Yefeng Cai; Xiaojia Ni
Journal:  Front Cardiovasc Med       Date:  2022-04-25

4.  Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study.

Authors:  Cristina Navarro-Soriano; Miguel-Angel Martínez-García; Gerard Torres; Ferrán Barbé; Candela Caballero-Eraso; Patricia Lloberes; Trinidad Diaz Cambriles; María Somoza; Juan F Masa; Mónica González; Eva Mañas; Mónica de la Peña; Francisco García-Río; Josep María Montserrat; Alfonso Muriel; Grace Oscullo; Laura Feced Olmos; Alberto García-Ortega; David Calhoun; Francisco Campos-Rodriguez
Journal:  Hypertens Res       Date:  2019-06-17       Impact factor: 3.872

5.  Metabolic phenotypes and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies.

Authors:  Golnoosh Goodarzi; Hadis Mozaffari; Tahereh Raeisi; Fatemeh Mehravar; Bahman Razi; Maryam Lafzi Ghazi; Nazila Garousi; Shahab Alizadeh; Parisa Janmohammadi
Journal:  BMC Cancer       Date:  2022-01-21       Impact factor: 4.430

6.  Interaction between mitochondrial NADH dehydrogenase subunit-2 5178 C > A and clinical risk factors on the susceptibility of essential hypertension in Chinese population.

Authors:  Xi Chen; Xiang-Yu He; Chao Zhu; Yusong Zhang; Zongbin Li; Yuqi Liu; Yuxiao Zhang; Tong Yin; Yang Li
Journal:  BMC Med Genet       Date:  2019-07-05       Impact factor: 2.103

7.  Visceral adiposity index performed better than traditional adiposity indicators in predicting unhealthy metabolic phenotype among Chinese children and adolescents.

Authors:  Yangyang Dong; Ling Bai; Rongrong Cai; Jinyu Zhou; Wenqing Ding
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

8.  Relationship between metabolically healthy obesity and the development of hypertension: a nationwide population-based study.

Authors:  Yue Yuan; Wei Sun; Xiangqing Kong
Journal:  Diabetol Metab Syndr       Date:  2022-10-13       Impact factor: 5.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.